CO6382114A2 - Inhibidores de cinasa akt y p70 s6 - Google Patents

Inhibidores de cinasa akt y p70 s6

Info

Publication number
CO6382114A2
CO6382114A2 CO11058555A CO11058555A CO6382114A2 CO 6382114 A2 CO6382114 A2 CO 6382114A2 CO 11058555 A CO11058555 A CO 11058555A CO 11058555 A CO11058555 A CO 11058555A CO 6382114 A2 CO6382114 A2 CO 6382114A2
Authority
CO
Colombia
Prior art keywords
akt
kinase inhibitors
formula
compounds
present
Prior art date
Application number
CO11058555A
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6382114A2 publication Critical patent/CO6382114A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CO11058555A 2008-11-11 2011-05-12 Inhibidores de cinasa akt y p70 s6 CO6382114A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
CO6382114A2 true CO6382114A2 (es) 2012-02-15

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058555A CO6382114A2 (es) 2008-11-11 2011-05-12 Inhibidores de cinasa akt y p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (https=)
EP (1) EP2358710B1 (https=)
JP (1) JP5432275B2 (https=)
KR (1) KR101334460B1 (https=)
CN (1) CN102216302B (https=)
AR (1) AR074072A1 (https=)
AU (1) AU2009314324B2 (https=)
BR (1) BRPI0921916A2 (https=)
CA (1) CA2743019C (https=)
CO (1) CO6382114A2 (https=)
CR (1) CR20110240A (https=)
CY (1) CY1113409T1 (https=)
DK (1) DK2358710T3 (https=)
DO (1) DOP2011000129A (https=)
EA (1) EA018947B1 (https=)
EC (1) ECSP11011048A (https=)
ES (1) ES2391704T3 (https=)
HN (1) HN2011001247A (https=)
HR (1) HRP20120738T1 (https=)
IL (1) IL211940A (https=)
JO (1) JO2822B1 (https=)
MA (1) MA32776B1 (https=)
MX (1) MX2011005000A (https=)
MY (1) MY161461A (https=)
NZ (1) NZ592062A (https=)
PA (1) PA8846901A1 (https=)
PE (1) PE20110807A1 (https=)
PL (1) PL2358710T3 (https=)
PT (1) PT2358710E (https=)
RS (1) RS52520B (https=)
SI (1) SI2358710T1 (https=)
TN (1) TN2011000207A1 (https=)
TW (1) TWI422587B (https=)
UA (1) UA100190C2 (https=)
WO (1) WO2010056563A1 (https=)
ZA (1) ZA201102549B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077364A1 (es) 2009-07-02 2011-08-24 Sanofi Aventis Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
CA2890288A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
AR093511A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US9434714B2 (en) * 2014-02-11 2016-09-06 Merck Patent Gmbh Pyrimidine imidazole amines as modulators of kinase activity
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
HUE055846T2 (hu) 2016-05-20 2021-12-28 Taiho Pharmaceutical Co Ltd Új 5H-pirrolo[2,3-D]pirimidin-6(7H)-on származék
TWI908780B (zh) * 2020-03-17 2025-12-21 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CN117940410A (zh) 2021-09-17 2024-04-26 江苏恒瑞医药股份有限公司 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
TW202421127A (zh) * 2022-07-05 2024-06-01 日商大鵬藥品工業股份有限公司 5H-吡咯并〔2,3-d〕嘧啶-6(7H)-酮及其鹽體之結晶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
TN2011000207A1 (en) 2012-12-17
AU2009314324A1 (en) 2010-05-20
EP2358710B1 (en) 2012-08-15
EA201170680A1 (ru) 2011-12-30
EP2358710A1 (en) 2011-08-24
US20100120801A1 (en) 2010-05-13
IL211940A0 (en) 2011-06-30
PT2358710E (pt) 2012-10-01
DK2358710T3 (da) 2012-09-03
JP5432275B2 (ja) 2014-03-05
TWI422587B (zh) 2014-01-11
HK1158203A1 (en) 2012-07-13
PL2358710T3 (pl) 2012-12-31
JO2822B1 (en) 2014-09-15
ES2391704T3 (es) 2012-11-29
MY161461A (en) 2017-04-14
TW201022268A (en) 2010-06-16
MA32776B1 (fr) 2011-11-01
DOP2011000129A (es) 2016-02-29
KR20110074578A (ko) 2011-06-30
AU2009314324B2 (en) 2013-06-20
CN102216302B (zh) 2013-08-21
CN102216302A (zh) 2011-10-12
UA100190C2 (en) 2012-11-26
US8148387B2 (en) 2012-04-03
PE20110807A1 (es) 2011-10-31
IL211940A (en) 2014-01-30
HN2011001247A (es) 2013-05-20
HRP20120738T1 (hr) 2012-10-31
MX2011005000A (es) 2011-05-25
JP2012508274A (ja) 2012-04-05
ZA201102549B (en) 2012-09-26
ECSP11011048A (es) 2011-06-30
PA8846901A1 (es) 2010-06-28
CR20110240A (es) 2011-06-09
EA018947B1 (ru) 2013-11-29
RS52520B (sr) 2013-04-30
CY1113409T1 (el) 2016-06-22
WO2010056563A1 (en) 2010-05-20
BRPI0921916A2 (pt) 2015-12-29
SI2358710T1 (sl) 2012-11-30
CA2743019C (en) 2013-08-13
AR074072A1 (es) 2010-12-22
KR101334460B1 (ko) 2013-12-02
NZ592062A (en) 2013-03-28
CA2743019A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CO6382114A2 (es) Inhibidores de cinasa akt y p70 s6
ECSP099721A (es) Inhibidores de cinasa p70 s6
BR112012011328A2 (pt) inibidores de akt
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
CR10782A (es) Compuestos para inhibir la progresion mitotica
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
BR112012008147A2 (pt) compostos heteroarílicos como inibidores da quinase
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
CR11433A (es) Inhibidores de quinasa c-fms
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
JO2673B1 (en) New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
CR20110075A (es) Agentes antifúngicos
MX2009003793A (es) Inhibidores de cinasa.
UA99739C2 (ru) Ингибиторы polo-подобных киназ
UY30343A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
HN2010000739A (es) Inhibidores de quinasa c-fms

Legal Events

Date Code Title Description
FG Application granted